The Lustgarten Foundation is the largest private funder of the world’s preeminent pancreatic cancer researchers.
To date, we have funded more than $250 million in research grants and been a leading force in every major advancement in pancreatic cancer research.
Progress is paramount. We drive bold, innovative research with the singular mission: transforming pancreatic cancer into a curable disease.
Lustgarten Announcements
This is it! Our year-end summary of how research, led by Lustgarten, is transforming pancreatic cancer into a curable disease. Join Lustgarten CEO Linda Tantawi and Andrew Rakeman, Vice President of Research, for an in-depth analysis with David Tuveson and Elizabeth Jaffee. Join us on THURSDAY, DECEMBER 8
November is Pancreatic Cancer Awareness Month, a month dedicated to spreading awareness and education about pancreatic cancer. This year, as the global leader in advancing treatment and cures, we encourage all supporters to join us as we recognize the relentless community, cutting-edge research, the importance of time and push for progress in our journey to […]
Welcome to Lustgarten LIVE; our live-streamed webinar series created to introduce you to best-in-class experts from the field of pancreatic cancer research, technology, and science. Here, you will find registration links for upcoming webinars and recordings of past ones.
News From Lustgarten
In an interview with Targeted Oncology™, Michael Chuong, MD, medical director of proton therapy and photon therapy, radiation, Baptist Health South Florida, discussed how 5 fractions of ablative radiation therapy compare with 15-25 fractions for the treatment of locally advanced pancreatic cancer.
When Houston resident Edgar Salazar began experiencing back pain, he didn’t pay a lot of attention. When he began having trouble eating, he became more concerned. When his stomach became swollen, he couldn’t keep food down and he began losing weight, he and his wife Joanna knew it was time to seek medical attention.
This is a randomized multicentre phase II trial with a large translational component. The trial will evaluate the two standard chemotherapy regimens: modified folfirinox (mFFX) and gemcitabine/nab-paclitaxel (GA), in patients with untreated metastatic pancreatic ductal adenocarcinoma. Integrated into this phase II trial are a number of laboratory components including molecular profiling, patient derived organoid establishment, […]
SUSAN’s story
From Nurse to Patient
When Susan was diagnosed with pancreatic cancer, cutting-edge drugs and a supportive medical team helped her go from patient to survivor. Now she raises funds for continued research through a Lustgarten Foundation Walk for Research.
Read Susan’s Story
